Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab

About this episode

This episode features an interview with the authors discussing the impact of neoadjuvant nivolumab on survival in HPV-negative head and neck squamous cell carcinoma.

Interview with Jennifer M. Johnson, MD, PhD and Adam J. Luginbuhl, MD authors of A Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab. Hosted by Paul C. Bryson, MD MBA. Related Content: Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab Emerging Role of Pathologic Response in Head and Neck Squamous Cell Carcinoma Immunotherapy

People in this episode

Host: Paul C. Bryson, MD MBA

Guests: Jennifer M. Johnson, MD, PhD, Adam J. Luginbuhl, MD

Topics covered

• HPV-Negative HNSCC
• Neoadjuvant Nivolumab
• Pathologic Treatment Effect
• Survival Rates
• Immunotherapy
• Head and Neck Cancer

Keywords

• HNSCC
• Nivolumab
• Pathologic Response
• Cancer Treatment
• Survival Analysis
• Immunotherapy

Mentioned in this episode

Books & works: A Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab

More episodes of JAMA Otolaryngology–Head & Neck Surgery Author Interviews

• Deep Learning in Otolaryngology · June 11, 2026 · 20 min
• Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer · May 21, 2026 · 16 min
• Federal Funding in Otolaryngology–Head and Neck Surgery · April 9, 2026 · 13 min
• Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma · March 26, 2026 · 12 min
• Why Hearing Health Must Be Part of Voice Biomarker Research · January 2, 2026 · 14 min
• Biofeedback vs Respiratory Retraining for Inducible Laryngeal Obstruction · December 11, 2025 · 16 min